Hanmi Pharm (128940) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, Hanmi Pharm (128940) reported revenue of 1.55 trillion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
20251.55 trillion KRW257.8 billion KRW187.1 billion KRW[source]
20241.50 trillion KRW216.2 billion KRW140.4 billion KRW[source]
20231.49 trillion KRW220.7 billion KRW165.4 billion KRW[source]
20221.33 trillion KRW158.1 billion KRW101.6 billion KRW[source]
20211.20 trillion KRW125.4 billion KRW81.5 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
20251.46 trillion KRW608.6 billion KRW856.1 billion KRW[source]
20241.41 trillion KRW672.2 billion KRW740.6 billion KRW[source]
20231.33 trillion KRW689.3 billion KRW641.2 billion KRW[source]
20221.40 trillion KRW813.5 billion KRW585.8 billion KRW[source]
20211.46 trillion KRW911.5 billion KRW546.8 billion KRW[source]

Cash Flow

YearOperatingInvestingFinancingSource
2025———[source]
2024———[source]
2023—-183.5 billion KRW—[source]
2022———[source]
2021———[source]

Cash flow figures for the relevant year were not collected.

Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice